Interaction between Alendronic acid and Magnesium oxide
Moderate Absorption

ID DDInter42 and DDInter1119
Interaction INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.
Management Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.
References
Alternative for Alendronic acid M05B
Romosozumab
Denosumab
Zoledronic acid
Pamidronic acid
Burosumab
Alternative for Magnesium oxide A12C
Sodium sulfate
Sodium chloride

A06A
Linaclotide
Lubiprostone
Naloxone
Mineral oil
Glycerin
Castor oil
Polyethylene glycol (3350 with electrolytes)
Plecanatide
Methylcellulose
More

Potential Metabolism Interactions

Substrate-Substrate Interaction：If more than one drug is metabolized by the same CYP, it is possible that its metabolism is inhibited because of the competition between the drugs. That means, it can be useful to lower the dosage of the drugs in the drug-cocktail because they remain longer in the organism than in monotherapy.
Inhibitor-Inhibitor Interaction：Combining two or more inhibitors of one CYP, should be compensated by lowering the dosage of these drugs because the metabolism is reduced and the drugs remain longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.
Inhibitor-Substrate Interaction：Combining drugs that have inhibitory effect and are substrates of one particular CYP, should be compensated by lowering the dosage. They rest longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.